Title
Stereo-selective inhibition of spinal morphine tolerance and hyperalgesia by an ultra-low dose of the alpha-2-adrenoceptor antagonist efaroxan.

Permalink
https://escholarship.org/uc/item/1sm240tt

Journal
European journal of pharmacology, 702(1-3)

ISSN
0014-2999

Authors
Milne, Brian
Jhamandas, Khem
Sutak, Maaja
et al.

Publication Date
2013-02-01

DOI
10.1016/j.ejphar.2013.01.022

License
CC BY 4.0

Peer reviewed
Neuropharmacology and analgesia

Stereo-selective inhibition of spinal morphine tolerance and hyperalgesia by an ultra-low dose of the alpha-2-adrenoceptor antagonist efaroxan

Brian Milne a,b,c, Khem Jhamandas a,b,c, Maaja Sutak b, Patrick Grenier b, Catherine M. Cahill a,b,c,d

a Departments of Anesthesiology and Perioperative Medicine, Queen’s University, Kingston, Ontario, Canada
b Biomedical and Molecular Sciences, Queen’s University, Kingston, Ontario, Canada
c Center for Neuroscience Studies, Queen’s University, Kingston, Ontario, Canada
d Department of Anesthesiology & Perioperative Care, University of California, Irvine, USA

A B S T R A C T

Ultra-low doses of alpha-2 (α2)-adrenoceptor antagonists augment spinal morphine antinociception and inhibit tolerance, but the role of receptor specificity in these actions is unknown. We used the stereo-isomers of the α2 adrenoceptor antagonist, efaroxan to evaluate the effect of receptor specificity on the induction of spinal morphine tolerance and hyperalgesia. Tail flick and paw pressure tests were first used to evaluate high dose efaroxan (12.6 μg) and its stereo-isomers on clonidine analgesia in intrathecally catheterized rats. Ultra-low doses of individual isomers (1.3 ng) were then co-administered with morphine (15 μg) to determine their effects on acute antinociceptive tolerance and hyperalgesia induced by low dose spinal morphine (0.05 ng). Results demonstrate that high dose (+) efaroxan antagonized clonidine-induced antinociception, while (−) efaroxan had minimal effect. In addition, an ultra-low dose of (+) efaroxan (1.3 ng), substantially lower than required for receptor blockade, inhibited the development of acute morphine tolerance, while (−) efaroxan was less effective. Racemic (+) efaroxan effects were similar to those of (+) efaroxan. Furthermore, low dose morphine (0.05 ng) produced sustained hyperalgesia in the tail flick test and this was blocked by co-injection of (+) but not (−) efaroxan (1.3 ng). Given the isomer-specific efaroxan effects and their different receptor potencies, we suggest that inhibition of opioid tolerance by ultra-low dose efaroxan involves a specific interaction with spinal α2-adrenoceptors in this model. Likewise, inhibitory effects of adrenoceptor antagonists on morphine tolerance may be due to blockade of opioid-induced hyperalgesia.

© 2013 Elsevier B.V. All rights reserved.

1. Introduction

Repeated systemic or spinal opioid administration produces analgesic tolerance (Christie, 2008), a phenomenon linked to the induction of progressive and latent hyperalgesia with a consequent loss of drug potency (Chu et al., 2006). Indeed, the outcome of analgesic tolerance is a complex phenomenon resulting in the activation of various opponent processes (Harrison et al., 1998; Zeng et al., 2006) including the onset of mechanisms leading to opioid-induced hyperalgesia (Chu et al., 2008) and opioid receptor desensitization (Connor et al., 2004).

Ultra-low dose of the opioid antagonist, naltrexone paradoxically inhibits development of opioid tolerance (Shen and Crain, 1997) (ultra-low dose is defined as a dose several log units lower than that required to produce functional antagonism at the respective receptors), a finding many other studies have replicated (Powell et al., 2002; Terner et al., 2006; McNaull et al., 2007). For example, ultra-low doses of competitive opioid receptor antagonists such as naltrexone have been shown to paradoxically augment spinal morphine analgesia and inhibit or reverse the development of this opioid tolerance (Powell et al., 2002; Chindalore et al., 2005; Mattioli et al., 2010). Interestingly, the ultra-low dose phenomenon is not restricted to opioid antagonists but is also produced by ultra-low dose adrenergic antagonists. Hence, we have shown that ultra-low dose α2 adrenoceptor antagonists both prevent and reverse established analgesic tolerance to morphine (Milne et al., 2008), a finding subsequently confirmed by Lilius et al. (2012). We have shown that ultra-low doses of structurally diverse α2-adrenoceptor antagonists (atipamezole, yohimbine, mirtazapine, and idazoxan) also increase the acute antinociceptive effects of morphine, block the induction of acute as well as chronic tolerance, and effectively reverse established tolerance to spinal morphine in tests of...
thermal and mechanical nociception (Milne et al., 2008). The basis of these unusual crossover effects of the adrenergic antagonists remains unknown, but may involve action on G-protein coupled receptor heteromeric complexes and/or conformational cross-talk (Jordan et al., 2003; Vilardaga et al., 2008).

In the present study, we aimed to determine whether the ultra-low dose effects of an $\alpha_2$ receptor antagonist to block acute morphine tolerance and opioid-induced hyperalgesia are receptor-mediated by using stereo-selective isomers. Efaroxan is a potent and selective $\alpha_2$-adrenoceptor antagonist whose dextro isomer (+) shows greater potency and activity than the levo isomer (−) at this receptor. The compound is a 2-ethyl-substituted idazoaxan analog, possessing a dihydrobenzofuranyl ring instead of a benzodiazoaxan ring. In $\alpha_2$-adrenoceptor binding experiments on the human frontal cortex, IC$_{50}$ values for efaroxan at the $\alpha_2$-adrenoceptor were reported to be $27 \pm 1.9$ nM for the (+) and $11,000 \pm 580$ nM for the (−) enantiomer (Flamez et al., 1997). In rats, bearing 6-hydroxydopamine-induced lesions of the nigrostriatal pathway, stereo-selective facilitating effects of the (+) enantiomer of efaroxan were demonstrated on circling behavior (Chopin et al., 1999). Thus, using the racemic (+/−) efaroxan and its stereoisomers we investigated whether (i) (+) and (−) efaroxan produce stereo-selective antagonistic effects on clonidine-induced antinociception in the acute thermal and mechanical nociception tests, (ii) doses of efaroxan stereo-isomers substantially below those producing $\alpha_2$-adrenoceptor antagonism block the development of acute spinal morphine tolerance, and (iii) ultra-low doses of efaroxan exhibit a stereo-selective action on hyperalgesia induced by a low dose of morphine (Crain and Shen, 2000; McNaul et al., 2007).

2. Materials and methods

2.1. Subjects

All experiments were performed on male Sprague–Dawley rats (250–300 g) obtained from Charles River Laboratories, Montreal QC, Canada following approval by the Queen’s University Animal Care Committee in accordance with the guidelines of the Canadian Council on Animal Care. Animals were given ad libitum access to food and water, and were maintained under a 12 h light/dark cycle at room temperature (21–23 °C). Animals were acclimatized for 3–4 days before surgery.

2.2. Intrathecal catheterization

Intrathecal catheters were implanted under halothane anesthesia using the method described by Yaksh and Rudy (1976). Briefly, the animal was placed prone in a stereotaxic frame, a small incision was made in the atlanto-occipital membrane of the cisterna magna and a polyethylene catheter (PE10; 7.5 cm) inserted through the opening such that the tip reached the lumbar enlargement of the spinal cord. To avoid potential interaction with the test compounds, rats did not receive an analgesic pre-surgery, but did receive lactated Ringer’s solution to prevent dehydration (5 ml, s.c.) and 0.04 ml/100 g Tribrissen 24% s.c. peri-operatively. Following surgery and recovery from the anesthetic, rats were returned to their cage with food and water available ad libitum (soft food was provided to any rat that did not appear to be eating well). Animals were monitored daily to inspect general appearance and any animal that showed signs of distress such as matted hair, spontaneous vocalization upon handling, or showing visible neurological deficits (forelimb or hind limb paralysis) was sacrificed immediately. Nylabone chew toys and a section of polyvinyl chloride (PVC) tubing was provided for environmental enrichment. Minor skin lesions were treated with gentocin violet solution. All animals were allowed to recover for 4–5 days prior to experimentation. Investigational drugs were injected, in a single blind fashion, through the rostral exteriorized portion of the catheter in a 10 μl volume and flushed with 10 μl of normal saline.

2.3. Nociception assessment

Following conditioning to the testing environment, antinociception was assessed using thermal tail flick and mechanical paw pressure tests. The tail flick test (D’Amour and Smith, 1941) measured the response to a brief thermal stimulus applied 5 cm from the base of the tail with the use of an antinociception meter (Owen et al., 1981). Time for tail removal from the thermal stimulus was recorded with baseline latency set at 2–3 s and a cut-off time of 10 s to prevent tissue damage. The paw pressure test measures response to a brief mechanical nociceptive stimulus applied to the dorsal hind paw using an inverted air-filled syringe connected to a pressure gauge (Loonis et al., 1987). Pressure was gradually increased until withdrawal occurred (baseline 70–90 mmHg, cut-off 300 mmHg) (Milne et al., 2008). All animals were habituated to the testing apparatus for at least 3 days prior to experimentation (Milne et al., 2008). Tail flick testing preceded paw pressure testing in each animal and prior experience has shown no significant interaction between responses in these tests (Loonis et al., 1987). In hyperalgesia experiments, only the tail flick test was utilized, using a lower stimulus intensity yielding a baseline latency response of 9–10 s (cut off 24 s), as holding and restraining these animals for paw pressure testing leads to increased variability in withdrawal thresholds such that data are inconsistent in demonstrating a mechanical hyperalgesic effect.

All behavioral testing was performed without knowledge of the treatments, and testing occurred between 0800 and 1400 h during the light cycle. Drug, drug isomer, and vehicle treatments were administered in the same experiment.

2.4. Experiment 1: effects of racemic efaroxan and its stereo-isomers on clonidine antinociception

To establish the antagonist effects of efaroxan at $\alpha_2$ receptors, efaroxan (12.6 μg or 1.3 μg) was administered concomitantly with clonidine (13.3 μg) via intrathecal (i.t.) injection through chronically implanted catheters. The effect of stereo-selective enantiomers (+) efaroxan (12.6 μg) and (−) efaroxan (12.6 μg) on clonidine-induced antinociception was also determined in both the tail flick and paw pressure tests.

2.5. Experiment 2: effect of ultra-low dose efaroxan and its stereo-isomers on acute spinal morphine tolerance

Acute tolerance to spinal morphine was induced by administration of three successive injections of intrathecal morphine (15 μg) delivered at 90 min intervals (McNaull et al., 2007). Thermal and mechanical response thresholds were recorded prior to and following drug injection using the tail flick and paw pressure tests respectively. Latencies to respond were evaluated at 30-min intervals since peak morphine effect in the tail flick and paw pressure tests occurs at this interval following drug injection (Powell et al., 2002; Milne et al., 2008).

To determine the effects of ultra-low dose efaroxan on morphine tolerance racemic (±) efaroxan (1.3 ng or 0.13 ng) or (+) efaroxan (1.3 ng) or (−) efaroxan (1.3 ng) were injected concomitantly with the first, second and third dose of intrathecal morphine in the acute morphine tolerance paradigm described
above. The ability of efaroxan to attenuate acute morphine tolerance was determined by the ability of the drug to influence both the magnitude of the morphine-elicited response on day 1 of the testing period and on the morphine ED\textsubscript{50} values obtained 24 h after repeated injections. Cumulative dose–response curves for the acute action of morphine were obtained 24 h after the repeated injections of morphine or morphine and efaroxan isomers to derive quantitative estimates of the opioid agonist potency (ED\textsubscript{50} values). Dose–response curves were obtained by administering ascending cumulative doses of morphine (2.5, 5, 10 and 20 μg morphine in efaroxan (1.3 or 0.13 ng) or efaroxan plus morphine treatment groups and 12.5, 25, 50 and 100 μg morphine in the repeated morphine-treatment group) at 30 min intervals until a maximal antinociceptive response was obtained. Morphine ED\textsubscript{50} values were derived from the dose–response curves obtained in these tests and calculated by linear regression using the Prism Graphpad software (version 4.0). The occurrence of antinociceptive tolerance was indicated by a progressive decrease in the magnitude of the antinociceptive effect produced by successive morphine injections (day 1), and a significant increase in the morphine ED\textsubscript{50} value (day 2) reflecting a loss of the agonist potency (Milne et al., 2008).

2.6. Experiment 3: effects of ultra-low doses of efaroxan stereoisomers and other \(\alpha_2\)-adrenoceptor antagonists on morphine hyperalgesia

Morphine hyperalgesia was induced by a single intrathecal injection of low dose morphine (0.05 ng) and analgesia assessed using the tail flick test (McNaught et al., 2007). In subsequent tests, morphine was co-injected with a dose (1.3 ng) of the efaroxan isomers evaluated in preceding experiments on tolerance, or with ultra-low doses of other \(\alpha_2\) receptor antagonists, atipamezole (0.08 ng) or yohimbine (0.02 ng), previously found to modulate acute morphine tolerance (Milne et al., 2008).

2.7. Data analysis

All tail flick and paw pressure values were converted to percentage of maximum possible effect (M.P.E.) (M.P.E. = 100 \times ([post-drug response – baseline response]/cutoff response – baseline response)). Data are expressed as mean ± S.E.M. for \(N=4–8\) per group. ED\textsubscript{50} values were determined using nonlinear regression analysis. A 2-way repeated-measures analysis of variance (ANOVA) with time as a within-subject factor and treatment as a between-subject factor was used to account for repeated measures design. Time X treatment interaction was included to test for differences in longitudinal response. Where applicable, Tukey's post-hoc tests were conducted.

2.8. Drugs

All drugs were dissolved in 0.9% sterile saline. Morphine sulfate (BDH Pharmaceuticals, Toronto, Canada), atipamezole (Farmos, Turku, Finland), yohimbine and clonidine (Sigma Chemical Co., St. Louis, MO, USA). The racemic efaroxan was obtained from Tocris Bioscience and efaroxan isomers were kindly provided by Dr. Marc Marien, Institut de Recherche Pierre Fabre, Castres, France.

3. Results

3.1. Actions of efaroxan and its stereoisomers on \(\alpha_2\)-adrenoceptor mediated analgesia

Intrathecal injection of clonidine (13.3 μg) produced an increase in withdrawal thresholds in both the tail flick and paw
pressure tests, with peak antinociceptive effects observed 30 min post-injection and a slow return towards baselines over the 180 min time course (Fig. 1A,B). The antinociceptive effects of clonidine were attenuated by co-administration of racemic (+) efaroxan (12.6 µg and 1.3 µg) compared to clonidine alone and this effect was greater with the higher dose (Fig. 1A, B). The effects produced by co-injection of stereo-isomers of efaroxan with clonidine demonstrate that (+) efaroxan (12.6 µg), the isomer with high binding affinity for α2-adrenoceptors, inhibited clonidine-induced antinociception (Fig. 1C, D) in both the tail flick and paw pressure tests. In contrast, when the (−) isomer of efaroxan was co-injected with clonidine, the resulting antinociceptive effects in the tail flick test were not significantly different compared to clonidine alone (Fig. 1C). However, in the paw pressure test (Fig. 1D), inhibition occurred with the (−) isomer, but to a lesser extent than with the (+) isomer. There was shorter onset of analgesia with clonidine and the (−) efaroxan combination.

3.2. Action of racemic (+) efaroxan on acute morphine tolerance

Intrathecal administration of morphine (15 µg) produced an increase in withdrawal thresholds in both the tail flick and paw pressure tests. Three successive morphine injections administered at 90-min intervals represents a valid protocol for acute opioid antinociceptive tolerance (McNaul et al., 2007) (Fig. 2A). Morphine co-administered with ultra-low dose racemic (+) efaroxan (1.3 ng) produced augmented antinociceptive effects at 60 min and 90 min following morphine injections at 90 and 180 min but there was no difference in peak antinociceptive effects at 30 min following each morphine injection compared to morphine alone (Fig. 2A). In the paw pressure test, morphine combined with ultra-low dose racemic (+) efaroxan produced sustained antinociceptive effects that were not different than peak antinociceptive effects of morphine at 30 min (Fig. 2B). Racemic (+) efaroxan alone (1.3 ng) did not produce significant effects on thermal tail flick latencies or paw withdrawal thresholds (Fig. 2A,B). Twenty-four hours following the acute morphine tolerance paradigm, all animals were exposed to cumulative injections of morphine to establish dose–response curves. Saline controls were not conducted for the current investigation but have been completed numerous times previously with no observed effect (Abul-Husn et al., 2007; Milne et al., 2008, 2011). Previous ED50 values obtained from cumulative dose–response curves in saline-treated rats were established at 5.5 and 5.9 µg for tail flick and paw pressure tests respectively (Milne et al., 2008). Co-treatment of animals with efaroxan (1.3 ng or 0.13 ng) significantly shifted the dose–response curves to the left indicating a reduction of antinociceptive tolerance in both the tail flick and paw pressure tests (Fig. 2C,D). The curve was apparently further left-shifted with 0.13 ng efaroxan

Fig. 2. Effect of racemic efaroxan on acute morphine tolerance: Tail flick (A) (n=4–8) and paw pressure (B) tests (n=4–8) were performed over a 240 min time course. Efaroxan injections were administered at 0, 90, and 180 min. Cumulative dose–response curves for tail flick (C) (n=4–8) and paw pressure (D) (n=4–8) tests were obtained by administering ascending cumulative doses of morphine at 30 min intervals until a maximal antinociceptive response was obtained. Morphine ED50 values were derived from the dose–response curves using linear regression analysis. ***P<0.001, **P<0.01, and *P<0.05.
Table 1
Effect of low dose i.t. efaroxan and its stereoisomers on the induction of acute tolerance to morphine.

| Treatment | Tail flick ED50 (µg i.t.) (mean ± S.E.M.) | Paw pressure ED50 (µg i.t.) (mean ± S.E.M.) |
|-----------|------------------------------------------|-------------------------------------------|
| Morphine (15 µg) | 28.92 ± 1.39 | 31.18 ± 1.62 |
| Morphine (15 µg) + Efaroxan (1.3 ng) | 4.42 ± 0.54* | 4.79 ± 0.27* |
| Efaroxan (1.3 ng) | 4.82 ± 0.47* | 5.45 ± 0.31* |
| Morphine (15 µg) + Efaroxan (0.13 ng) | 2.55 ± 0.36* | 4.72 ± 1.30* |
| Efaroxan (0.13 ng) | 3.60 ± 0.19* | 3.60 ± 0.50* |

Fig. 2
Morphine (15 µg) | 28.92 ± 1.39 | 31.18 ± 1.62 |
Morphine (15 µg) + (+) Efaroxan (1.3 ng) | 2.46 ± 0.20* | 3.5 ± 0.37* |
Morphine (15 µg) + (−) Efaroxan (1.3 ng) | 19.31 ± 0.42a | 20 ± 1.06a |
(+) Efaroxan (1.3 ng) | 4.68 ± 0.43b | 7.04 ± 0.74b |
(−) Efaroxan (1.3 ng) | 2.47 ± 0.28b | 2.6 ± 0.30b |

Table 1 lists the ED50 values from the dose–response curves in both the tail flick and paw pressure tests from Fig. 3.

3.4. Attenuation of low dose morphine hyperalgesia with ultra-low-dose alpha 2 receptor antagonists

To investigate changes in the development of opioid hyperalgesia, an ultra-low dose of morphine (0.05 ng) was administered intrathecally, alone or in combination with a low dose of an α2 receptor antagonist. Opioid hyperalgesia was observed after the first 90 min after morphine injection (0.05 ng) as evidenced by a negative change in %M.P.E. After 120 min antinociceptive effects were produced with maximal effect observed 210 min post injection (Fig. 4A,B). Morphine co-administered with low dose (+) efaroxan stereo-isomer (1.3 ng) significantly attenuated morphine-induced hyperalgesia, while co-administration of the (−) efaroxan isomer (1.3 ng) had no effect (Fig. 4A). Interestingly, co-administration with an ultra-low dose of other α2-adrenoceptor antagonists (atipamezole (0.08 ng) or yohimbine (0.02 ng)) also inhibited morphine-induced hyperalgesia causing analgesia at approximately 60 min after their administration (Fig. 4B). The maximal effect of morphine-induced antinociception was delayed but the maximal response achieved after 120 min was not influenced.

4. Discussion

The current investigation demonstrates that the α2-adrenoceptor antagonist efaroxan effectively inhibits the antinociceptive effects of clonidine in thermal and mechanical nociceptive tests. In addition, repeated acute administration of spinal morphine induced antinociceptive tolerance was effectively blocked by an ultra-low dose of the active (+) isomer of efaroxan. The dose that was effective in attenuating the development of antinociceptive tolerance also suppressed thermal hyperalgesia elicited by a low dose of intrathecal morphine.

The present study used a model of acute morphine tolerance and efaroxan stereo-isomers (with different receptor affinities) to investigate whether the actions of an α2-adrenoceptor antagonist in modulating opioid analgesia and tolerance are due to interaction at the α2-adrenoceptor. In the present study, ultra-low doses of the α2 antagonist efaroxan inhibited the development of acute morphine tolerance, an effect reflected in both the maintenance of the opioid-induced response to repeated drug administration and prevention of the loss of agonist potency. Previous evidence implicating α2 receptors in opioid analgesic tolerance was based on the actions of atipamezole, a highly selective α2 antagonist (Milne et al., 2008, Lilius et al., 2012) and reinforced by replication of these major findings with other ligands including yohimbine, idazoxan and mirtazapine that are less selective, but have the common ability to block α2 receptors (see Milne et al., 2008). The present study demonstrates that the effects of ultra-low dose efaroxan were stereo-selective in the thermal acute tolerance test, suggesting that the inhibition of tolerance by ultra-low doses of the antagonist indeed involves a specific interaction with spinal α2-adrenoceptors. In this study, efaroxan was chosen because of strong evidence for its stereo-selectivity in both binding studies (Flamez et al., 1997) and in vivo studies not involving nociception (Chopin et al., 1999).
Overall, the data demonstrate that the development of both tolerance and hyperalgesia is largely stereo-specific, suggesting the effects of efaroxan were produced by inhibition of a2-adrenoceptors. While the stereo-selectivity displayed by pharmacological systems constitutes the best evidence that receptors exist and that they incorporate concrete molecular entities as integral components of their active sites (Lehmann, 1982), the stereo-selective action of isomers is not absolute. This may explain some of the partial effects of (−) efaroxan in its effect on acute morphine tolerance in the paw pressure test. (−) efaroxan is the “less active” isomer as reflected in binding studies (Flamez et al., 1997). The use of ultra-low doses, however, potentially calls into question whether the effects are mediated via activity at adrenoceptors, since much larger doses are required to antagonize an adrenergic agonist. While stereo-selectivity is confirmed, the precise receptor remains elusive in the absence of binding studies to confirm significant binding affinity with a2-adrenoreceptors at such low concentrations, as those used in our experiments.

Ultra-low dose racemic efaroxan alone produced delayed analgesia in the paw pressure test at 240 min. We do not have a good explanation for this effect although the delayed antinociception may possibly be due to an interaction of efaroxan with endogenous opiates released during repeated testing. Interestingly, BRL 44408, a highly selective a2A adrenoceptor antagonist has been recently shown to exhibit analgesia in a model of visceral pain. The authors (Dwyer et al., 2010) suggest that selective a2A-adrenoceptor antagonism, (either by direct inhibition of a2A autoreceptors or through a heteroceptor function of a2A-adrenoceptors) may be useful in pain therapy. It is conceivable that efaroxan may have similar actions.

The mechanism by which ultra-low dose a2 antagonists inhibit the development of acute morphine tolerance is unknown, although it is well accepted that there are interactions between these G-protein coupled receptors. Thus, agonists of mu opioid and a2 receptors produce a synergistic effect in that the activation with a2 agonists augments opioid-induced antinociception in rodents (Fairbanks et al., 2002; Tajerian et al., in press), and such combination has been proven beneficial in clinical practice whereby effective pain treatment was reported with reduced side effects when clonidine was combined with an opioid agonist (Eisanach et al., 1994; Paech et al., 2004). Additionally, morphine-induced antinociception recruits a2 receptors as demonstrated by reduced analgesic potency in a2A null mutant mice (D79N point mutation) compared to wild type animals (Stone et al., 1997). In addition to functional synergistic interactions, mu opioid receptors have been shown to form heteromers with several G protein coupled receptors involved in pain regulation including the a2 receptors (Gupta et al., 2006; Jordan et al., 2003). Such interactions have been reported to occur not only in the spinal cord but...
Vilardaga et al., 2008) may allow for the ultra-low dose of efaroxan isomers (1.3 ng) (A) (Lee et al., 2011)) or other $\sigma_2$ receptor antagonists, atipamezole (0.08 ng) or yohimbine (0.02 ng) (B) (n=5–6). $$P<0.001, \quad ^*P<0.01, \quad ^*P<0.05$$ compared to morphine (0.05 ng).

Fig. 4. Attenuation of morphine hyperalgesia with low dose $\sigma_2$ antagonists: Thermal tail flick responses were assessed over a 240 min time course following a single intrathecal injection of low dose morphine (0.05 ng) either alone or co-administered with an ultra-low dose of efaroxan isomers (1.3 ng) (A) (n=5–6) or other $\sigma_2$ receptor antagonists: Thermal tail flick responses were assessed over a 240 min time course following a single intrathecal injection of low dose morphine (0.05 ng) either alone or co-administered with an ultra-low dose of efaroxan isomers (1.3 ng) (A) (n=5–6) or other $\sigma_2$ receptor antagonists: atipamezole (0.08 ng) or yohimbine (0.02 ng) (B) (n=5–6). $$P<0.001, \quad ^*P<0.01, \quad ^*P<0.05$$ compared to morphine (0.05 ng).

also at the level of the primary afferent neurons and other CNS sites (Iglesias and Norenberg, 1990). These receptors, either singly or as a heterodimer, activate common signal transduction pathways mediated through the inhibitory G proteins (G{i} and G{o}). However, there is evidence that continued opioid exposure of neurons in culture (Crain and Shen, 1996) or prolonged administration of opioids in vivo (Crain and Shen, 2000) could paradoxically produce facilitatory effects via activation of stimulatory G proteins (G{s}). Similarly, the hyperalgesic effects produced by low dose intrathecal morphine may also involve opioid receptor activation of Gs (McNaull et al., 2007; Esmaili-Mahani et al., 2008). One of the mechanisms that may underlie the effects of the ultra-low dose $\sigma_2$ antagonists is to prevent the mu opioid receptor from coupling to stimulatory effector systems that are initiated via activation of Gs. Such an effect could account for the ability of the stereoselective effects of efaroxan to block the induction of thermal hyperalgesia resulting from a low dose of spinal morphine, as well as acute opioid tolerance. Alternatively, conformational cross-talking control signaling between $\sigma_2$ and mu-opioid receptors (Vilardaga et al., 2008) may allow for the ultra-low dose of $\sigma_2$ antagonists to augment the interaction of the mu receptor with its ligand. It is also relevant to consider the possibility of efaroxan producing its effects via the imidazoline receptor. Hence, clonidine is an agonist at $\sigma_2$ as well as imidazoline receptors (Reis and Piletz, 1997). However, both stereo-isomers of the alkoxy-substituted imidazoline derivative efaroxan displays low affinity for imidazoline receptors (Vauquelin et al., 1999), thus making it unlikely that this would be a potential mechanism for the effects produced in the present study.

It is also worth considering the aspect of opioid-induced hyperalgesia and whether such phenomenon occurs in an acute opioid tolerance model. Previous studies have suggested the induction of hyperalgesia as a contributing factor in the development of acute opioid tolerance (see McNaull et al., 2007). Many mechanisms have been proposed to mediate opioid-induced hyperalgesia (Lee et al., 2011; Angst and Clark, 2006) and involve the activation of opponent processes (Bryant et al., 2005). A single dose of morphine (Goldfarb et al., 1978) or heroin (Celerier et al., 2001) can generate naloxone-precipitated hyperalgesia that has been replicated in non-addicted humans following a single injection of morphine (Compton et al., 2003). Similar effects are reported following remifentanil infusion for anesthesia (Guignard et al., 2000). Under these conditions, hyperalgesia has been associated with increased amplitude of spinal cord reflexes (Goldfarb et al., 1978) and increased activity of nociceptive facilitatory neurons in the medulla (Neubert et al., 2004), each of which effectively results in increased pain behaviors. Hence, the doses of morphine used in the acute tolerance study may recruit opponent processes that initiate a hyperalgesic state, and whether such mechanisms are similar to low-dose morphine-induced hyperalgesia remains unknown. However, ultra-low dose $\sigma_2$ antagonists appear to mitigate the genesis of such processes.

It is noteworthy that the less active stereoisomer of efaroxan partially inhibited the development of opioid tolerance in the mechanical nociceptive test and partially shifted the dose response curve for morphine following the acute tolerance paradigm. This is consistent with stereo-selectivity not being absolute as stated previously and may potentially explain the absence of complete stereo-specificity across the tests. There is no evidence to suggest that mechanisms of opioid tolerance differ between nociceptive modalities, however, it is not uncommon that opioid-induced mechanical hyperalgesia is reported more often than warm thermal hyperalgesia in clinical studies of healthy human subjects (Schmidt et al., 2007). Thus, mechanical tests may be more sensitive to detect the presence of opioid-induced hyperalgesia. In the present study, all animals were catheterized for spinal delivery of drugs and such catheterization causes neuro-inflammation (DeLeo et al., 1997) and can facilitate the development of opioid tolerance (Mattioli et al., 2012). Therefore, the catheter-induced neuro-inflammation may have sensitized nociceptive neurons that facilitated opioid-induced hyperalgesia in the acute opioid tolerance model.

5. Conclusion

The present study shows concomitant administration of an exceedingly low dose of an $\sigma_2$ antagonist can inhibit the development of acute opioid analgesic tolerance and low dose morphine-induced thermal hyperalgesia in a stereo-selective manner. This result suggests that the effects are indeed via an interaction between the opioid and adrenergic system rather than an alternative receptor pathway. It is not known if such processes occur in a chronic tolerance model although our previous experiments have demonstrated the ability of similar low doses of diverse, chemically distinct $\sigma_2$ antagonists to prevent and reverse established antinociceptive tolerance following chronic morphine administration (Milne et al., 2008). It is also unknown if this interaction is specific to spinal sites and merits further investigation as to whether systemic administration of these ligands will produce similar effects.

Disclosures/conflicts of interest

The research reported in this manuscript is similar in nature to that for which patent applications have been filed by PARTEQ, Queen’s University, Kingston, Ontario, Canada presented in part at the Society for Neuroscience Annual meeting, Abstract 678, San Diego, California, USA. November 13–17, 2010.
Role of funding source

This work was supported by grants from the Canadian Institutes of Health Research (CIHR) and The Canada Research Chairs Program.

Acknowledgments

The authors would like to thank Phelan for her assistance in preparation of this manuscript and Dr. Marc Marien and the Institut de Recherche Pierre Fabre, Castres, France for generously providing the efaroxan isomers for this work.

References

Abul-Husn, N.S., Sutak, M., Milne, B., Jhamandas, K. 2007. Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of m- and o- opioid receptor agonists. Br. J. Pharmacol. 151, 877–887.

Angst, M.S., Clark, J.D., 2006. Opioid-induced hyperalgesia: a qualitative systematic review. Anaesthesiology 104, 570–587.

Bryant, C.D., Zaki, P.A., Carroll, F.J., Evans, C.J., 2005. Opioids and addiction: emerging pharmacological strategies for reducing reward and opponent processes. Clin. Neurosci. Res. 5, 103–115.

Celerier, E., Laulin, J.P., Corcuff, J.B., Le Meaul, M., Simonnet, G., 2001. Progressive enhancement of delayed hyperalgesia induced by repeated heroin administration in mice. J. Neurosci. 21, 4074–4080.

Chindalond, V.L., Graven, R.A., Yu, K.P., Butera, P.G., Burns, L.H., Friedmann, N., 2005. Adding ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia, a randomized, controlled trial of Dextroxicin. Pain 6, 392–399.

Chopin, P., Colpaert, F.C., Marien, M., 1999. Effects of alpha-2 adrenergic agonists and antagonists on circling behavior in rats with unilateral 6-hydroxydopamine lesions of the nigrostriatal pathway. J. Pharmacol. Exp. Ther. 288, 798–804.

Christie, M.J., 2005. Cellular neuroadaptations to chronic opioids: tolerance, withdrawal and addiction. Br. J. Pharmacol. 144, 685–698.

Crain, S.M., Shen, K.F., 2000. Antagonists of excitatory opioid receptor functions enhance morphine’s analgesic potency and attenuate opioid tolerance/dependence liability. Pain 84, 121–131.

Crain, S.M., Shen, K.F., 1996. Modulatory effects of G-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence. Neurochem. Res. 21, 1347–1351.

D’Amour, F., Smith, D.L., 1941. A method for determining loss of pain sensation. J. Pharmacol. Exp. Ther. 72, 74–79.

DeLeo, J.A., Colburn, R.W., Rickman, A.J., Yeager, M.P., 1997. Intrathecal catheterization alone induces neuroimmune activation in the rat. Eur. J. Pain 1, 115–122.

Dwyer, J.M., Platt, B.J., Sukoff Rizzo, S.J., et al., 2010. Preclinical characterization of BR 444048: antidepressant- and analgesic-like activity through selective α2A-adrenergic antagonist action. J. Neurosci. 13 (9), 1193–1205.

Eisenach, J.C., D’Angelo, R., Taylor, C., 1998. An isobolographic study of strategies for screening and drug development. APS J. 8, E115–E159.

Harrison, L.M., Kastin, A.J., Zadina, J.E., 1998. Opiate tolerance and dependence: receptors, G-proteins, and antiopesiates. Peptides 19, 1603–1630.

Holl, P., Noreen, W., 1990. Blockade of α2-adrenoreceptors increases opioid µ-receptor-mediated inhibition of the firing rate of rat locus coeruleus neurons. Naunyn-Schmiedebergs Arch. Pharmacol. 342, 490–496.

Jordan, B.A., Gomes, I., Rios, C., Filipovska, J., Devi, L.A., 2003. Functional interactions between µ and α2-adrenergic receptors. Mol. Pharmacol. 64, 613–624.

Lee, M., Silverman, M.S., Hansen, H., Patel, V.B., Manchukanti, L., 2011. A comprehensive review of opioid-induced hyperalgesia. Pain Physician 14, 145–161.

Lehmann, P.A., 1982. Quantifying stereo-selectivity or how to choose a pair of shoes when you have two left feet. Trends Pharmacol. Sci. 3, 103–109.

Lilius, T.O., Rauhala, P.V., Kambr, D., Roth, K., Vananen, A.J., Kato, E.A., 2012. Intrathecal atipamezole augments the antinociceptive effect of morphine in rats. Anesth. Analg. 114, 1353–1358.

Loomis, C.W., Milne, B., Cerkenovo, F.W., 1987. Determination of cross tolerance in rats morphine and intrathecal infusion via sequential minis-oemotic pumps. Pharmacol. Biochem. Behav. 26, 131–139.

Mattioli, T.A., Sutak, M., Milne, B., Jhamandas, K., Cahill, C.M., 2012. Intrathecal catherization influences tolerance to chronic morphine in rats. Anesth. Analg. 114, 600–609.

Mattioli, T.A., Milne, B., Cahill, C.M., 2010. Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats. Mol. Pain 6, 22–33.

McNaul, B., Trang, T., Sutak, M., Jhamandas, K., 2007. Inhibition of tolerance to spinal morphine analgesia by low doses of opioid receptor antagonists. Eur. J. Pharmacol. 560, 132–141.

Milne, B., Sutak, M., Cahill, C.M., Jhamandas, K., 2008. Low doses of alpha-2-adrenoreceptor antagonists augment spinal morphine analgesia and inhibit development of acute and chronic tolerance. Br. J. Pharmacol. 155, 1264–1278.

Milne, B., Sutak, M., Cahill, C.M., Jhamandas, K., 2011. Low dose alpha-2 antagonist paradoxically enhances rat norepinephrine and clonidine analgesia. Anesth. Analg. 112 (6), 1500–1503.

Neumayer, L.H., Kincaid, W., Heinricher, M.M., 2004. Nociceptive facilitating neurons in the rostral ventromedial medulla. Pain 110, 158–165.

Owen, J.A., Milne, B., Jhamandas, K., Nakatsu, K., 1981. Assembly of an inexpensive tail flick analyzer. J. Pharmacol. Methods 6 (1), 33–37.

Paech, M., Pavy, T.J., Orlikowski, C.E., Yee, S.T., Banks, S.L., Evans, S.F., Henderson, J., 2004. Postcesarean analgesia with spinal morphine, clonidine, or their combination. Anesth. Analg. 98, 1460–1466.

Powell, K.J., Abul-Husn, N.S., Jhamandas, A., Olimstead, M.C., Beninger, R.J., Jhamandas, K., 2002. Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance and reward in rats. J. Pharmacol. Exp. Ther. 300, 588–596.

Reis, D.J., Pilete, J.E., 1997. The imidazoline receptor in control of blood pressure by clonidine and allied drugs. Am. J. Physiol. 273 (5 Pt 2), R1569–R1571.

Schnipper, L.J., Sethge, C., Foreman, S.A., Schaefer, M., 2007. Enhanced postsynaptic sensitivity to painful pressure stimulation after intraoperative high dose remifentanil in patients without significant surgical site pain. Clin. J. Pain 23, 605–611.

Shen, K.F., Crain, S.M., 1997. Ultra-low doses of naltrexone or etorphine increase morphine’s antinociceptive potency and attenuate tolerance/dependence in mice. Brain Res. 757, 176–190.

Stone, L.S., MacMillan, L.B., Kitto, K.F., Limbird, L.E., Wilcox, G.L., 1997. The alpha-2A adrenergic receptor subtype mediates spinal analgesia evoked by alpha-2 agonists and is necessary for spinal adrenergic-opioid synergy. J. Neurosci. 17, 7157–7165.

Tagerian, M., Millecamp, M., Stone, L.S., 2012. Morphine and clonidine synergize to ameliorate low back pain in mice. Pain Res. Treat. http://dx.doi.org/10.1155/2012/158042, in press.

Terner, J.M., Barrett, A.C., Lomas, L.M., Negus, S.S., Picker, M.J., 2006. Influence of low doses of naltrexone on morphine antinociception and morphine tolerance in male and female rats of four strains. Pain 122, 90–101.

Vazquez, G., De Backer, J.P., Lahude, P., Flamez, A., 1999. Identification of 11 and 12 imidazoline receptors in striatum membranes from different species. Ann. NY Acad. Sci. 881, 135–143.

Vilardaga, J.P., Nikolaev, V.O., Lorenz, K., Ferrandon, S., Zhuang, Z., Lobhe, M., 2008. Conformational cross-talk between alpha-2A adrenergic and mu-opioid receptors controls cell signaling. Nat. Chem. Biol. 4, 126–131.

Yaksh, T.L., Rudy, T.A., 1976. Chronic catheterization of the spinal subarachnoid space. Physiol. Behav. 17, 1031–1036.

Zeng, J., Thomson, L.M., Aicher, S.A., Terman, G.W., 2006. Primary afferent NMDA receptors increase dorsal horn excitation and mediate opiate tolerance in neonatal rats. J. Neurosci. 26, 12033–12042.